10,470 million baht or 11% of total accounts receivable, comparing to that of 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. The delinquent account receivables
there are any newly issued shares remaining after the allocation of shares to the existing shareholders in proportion to their shareholdings in the first round, the Company will allocate such remaining
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
cost was 10.05 Million Baht or an increase of 7.18 Million Baht which is equivalent to an increase of 250.17 % from the previous year. For the period of six months of the fiscal year 2017, the Company's
August 15, 2017 Subject: MD&A for the financial statements of the 2nd quarter of fiscal year 2017 ended as of June 30, 2017 To: The President The Stock Exchange of Thailand Aapico Hitech Public Company
year. For the period of nine months of the fiscal year 2017, the Company's financing cost was 42.48 Million Baht, increased by 32.67 Million Baht, or up by 333.03% from the previous year. The result was
) AAPICO HITECH PUBLIC COMPANY LIMITED Ref No: AH 01032020 March 3, 2020 Subject: Management Discussion & Analysis (MD&A) for the financial statements of fiscal year 2019 ended as of December 31, 2019 To
quarter of fiscal year 2019 ended as of June 30, 2019 To: The President The Stock Exchange of Thailand Aapico Hitech Public Company Limited (“the Company”) would like to clarify the consolidated financial